BECAS
CORDOBA Elisa Eugenia
congresos y reuniones científicas
Título:
Polymorphic Variant TP53 (R72P) May Suggest Acute Radiotoxicity in Breast Cancer Patients Undergoing Conventional Radiation Treatments?
Autor/es:
CÓRDOBA EE; ABBA MC; FERNÁNDEZ E; LACUNZA E; FINKELSTEIN SE; GÜERCI AM
Lugar:
San Francisco
Reunión:
Congreso; ASTRO's 56th Annual Meeting; 2014
Institución organizadora:
American Society for Radiation Oncology
Resumen:
Purpose/Objective(s): Numerous studies have suggested that individual radiosensitivity is a complex phenotype dependent on the interplay of genes related to DNA repair or enzymes involved in anti-oxidative activities. Thus, much interest lies in developing genetic analysis that predicts a patient?s probability of suffering toxicity following radiation therapy. The objective of this discovery study was to evaluate the potential association between candidate single nucleotide polymorphisms (SNPs) related response to radiation therapy injury in breast cancer patients undergoing conventional whole breast radiation. Materials/Methods: Fifty seven samples in the discovery set were analyzed from patients with early stage breast cancer who underwent breast-conserving surgery followed by whole breast radiation to a total dose of 5040 cGy delivered in 180 cGy daily fractions. Whole breast radiation treatments were conducted with a linear accelerator. DNA extraction was performed from peripheral blood or buccal swab. All individuals were genotyped for SNPs in GSTP1 (I105V), NOS3 (G298A), SOD2 (V16A), and TP53 (R72P) by RFLP-PCR. Univariate analysis (ORs and 95% CI) was performed to correlate SNPs with the risk of developing grade 1 acute skin reactions. Results: A significant relationship between polymorphic variant TP53 (R72P) and a risk of developing grade 1 acute skin reactions was seen (p: 0.043). There was no demonstrated association with polymorphisms of oxidative stress enzymes tested. Conclusions: This discovery study suggests a significant relationship between polymorphic variant TP53 (R72P) and a risk of developing grade 1 acute skin reactions. Further verification study to interrogate clinical relevance is currently in process.
